New Drugs for Treatment of Parkinson’s Disease

The pathology of Parkinson’s disease is not well understood but it is clearly linked to the misfolding and aggregation of the protein α -synuclein in neuronal cells. The inventors through their knowledge of α–synuclein druggability have developed new drugs that bind α–synuclein with high affinity and prevent protein aggregation making them promising leads to treat or slow the progression of Parkinson’s disease.